4//SEC Filing
Gano Kyle 4
Accession 0001567160-26-000002
CIK 0000914475other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 6:56 PM ET
Size
14.1 KB
Accession
0001567160-26-000002
Insider Transaction Report
Form 4
Gano Kyle
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-16$35.99/sh+34,588$1,244,822→ 174,995 total - Sale
Common Stock
[F1][F2]2026-01-16$132.70/sh−34,588$4,589,980→ 140,407 total - Exercise/Conversion
Common Stock
2026-01-16$35.99/sh+1,812$65,214→ 142,219 total - Sale
Common Stock
[F1][F3]2026-01-16$132.71/sh−1,812$240,478→ 140,407 total - Exercise/Conversion
Non-Qualified Stock Option
[F4]2026-01-16−34,588→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (34,588 underlying) - Exercise/Conversion
Incentive Stock Option
[F4]2026-01-16−1,812→ 0 totalExercise: $35.99Exp: 2026-02-05→ Common Stock (1,812 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F4]The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.
Signature
/s/ Darin Lippoldt, Attorney-in-Fact|2026-01-20
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001567160
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 6:56 PM ET
- Size
- 14.1 KB